EBS - Emergent BioSolutions Inc.
| Previous Close | 66.00 |
| Open | 65.88 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1300 |
| Day's Range | 65.03 - 66.47 |
| 52 Week Range | 36.38 - 67.24 |
| Volume | 2,030,969 |
| Avg. Volume | 324,731 |
| Market Cap | 3.299B |
| Beta | 1.64 |
| PE Ratio (TTM) | 29.43 |
| EPS (TTM) | 2.24 |
| Earnings Date | Oct 31, 2018 - Nov 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.43 |
- ACCESSWIRE•5 days ago
Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Emergent BioSolutions
On Thursday, President Donald Trump instructed aides to carry on with $200 billion tariffs against Chinese goods. “Between high corporate profits, stock buybacks, and muted interest rates, there’s still an underlying bid to the market no matter how you slice it. Arena Pharmaceuticals' stock jumped 3.33% Friday, to close the day at $42.18.
Markit•7 days agoSee what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- GuruFocus.com•15 days ago
Emergent Biosolutions Inc (EBS) CEO Daniel Abdun-nabi Sold $5.5 million of Shares
CEO of Emergent Biosolutions Inc (NYSE:EBS) Daniel Abdun-nabi sold 90,776 shares of EBS on 09/05/2018 at an average price of $60.18 a share.
- GlobeNewswire•17 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within Emergent Biosolutions, LGI Homes, Surgery Partners, Overseas Shipholding Group, National Commerce, and comScore — New Research Emphasizes Economic Growth
NEW YORK, Sept. 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- American City Business Journals•24 days ago
Why Emergent BioSolutions is jumping into the opioid crisis with new acquisition
Emergent BioSolutions Inc. just made another acquisition, and it’s joining the fight against the opioid crisis. The Gaithersburg biotech has reached an agreement to acquire Adapt Pharma Inc., the private company behind a nasal spray to treat emergency opioid overdose, in a transaction totaling $735 million, the company announced Tuesday. Adapt Pharma’s flagship product, Narcan Nasal Spray, uses naloxone to reverse the effects of opioid overdose.
- Bloomberg•24 days ago
New Narcan Owner Sees Schools as Growth Area for Overdose Spray
Emergent BioSolutions Inc. Chief Executive Officer Daniel J. Abdun-Nabi said he sees an untapped market in U.S. high schools and colleges for Narcan, the opioid-overdose nasal spray his company will market after its acquisition of Adapt Pharma Inc. Narcan is available in 1,144 high schools across 31 states and 309 colleges and universities in 35 states, Abdun-Nabi said Wednesday in an interview.
- Simply Wall St.•24 days ago
Is Emergent BioSolutions Inc (NYSE:EBS) Worth US$61.53 Based On Intrinsic Value?
I am going to run you through how I calculated the intrinsic value of Emergent BioSolutions Inc (NYSE:EBS) by taking the expected future cash flows and discounting them to theirRead More...
- Zacks•24 days ago
Emergent (EBS) to Buy Narcan Maker Adapt Pharma for $735M
Emergent (EBS) inks a deal to buy Adapt Pharma. This move will add the latter's popular Narcan nasal spray to its portfolio.
- Benzinga•24 days ago
The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Stocks hitting 52-week highs on Aug. 28) Abbott Laboratories (NYSE: ABT ) Affimed NV (NASDAQ: AFMD )(announced ...
- Reuters•24 days ago
Emergent BioSolutions to buy Narcan maker Adapt Pharma
Addiction to opioids - mainly prescription painkillers, heroin and fentanyl - has emerged as a serious public health crisis in the United States, especially in rural areas. President Donald Trump in March recommended death penalty for drug dealers after declaring the addiction crisis a public health emergency in October. Trump also introduced an Adapt Pharma executive, Mike Kelly, during an event in New Hampshire and said he wanted to give first responders access to life-saving drugs that can reverse overdoses.
- Reuters•24 days ago
Emergent BioSolutions to buy Narcan maker Adapt Pharma
Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA approved needle-free emergency opioid overdose treatment. Addiction to opioids - mainly prescription painkillers, heroin and fentanyl - has emerged as a serious public health crisis in the United States, especially in rural areas. According to the U.S. Centers For Disease Control And Prevention, the epidemic https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htmclaimed over 70,000 lives last year.
- Bloomberg•24 days ago
Narcan Maker Adapt to Be Acquired by Emergent BioSolutions
The maker of Narcan, the opioid-overdose antidote that’s been widely used across the U.S. to combat the nation’s addiction crisis, will be acquired by Emergent BioSolutions Inc. Emergent said the $735 million deal for Adapt Pharma, which includes a $635 million upfront payment and as much as $100 million in potential sales-based milestones, will expand the use of the nasal spray while maintaining its affordability and raising awareness of naloxone, the generic name for Narcan. Last year, President Donald Trump declared the opioid crisis a public health emergency, and the administration has announced plans to provide grant money for combating the crisis.
- Reuters•24 days ago
Emergent BioSolutions to buy Adapt Pharma for up to $735 mln
Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma for up to $735 million to acquire its drug Narcan, the only needle-free emergency treatment approved to treat opioid overdose. ...
- MarketWatch•24 days ago
Emergent BioSolutions agrees to buy Narcan spray maker Adapt Pharma for $735 million
Emergent BioSolutions Inc. (ebs) said late Tuesday it has entered an agreement to buy Adapt Pharma, including Adapt's flagship product Narcan nasal spray, for up to $735 million. Narcan nasal spray is the only needle-free formulation of naloxone approved by the U.S. Food and Drug Administration and Canadian health authorities for the emergency treatment of opioid overdoses. The deal would consist of an upfront payment of $635 million and up to $100 million in cash for future sales-based milestones through 2022.
- GlobeNewswire•25 days ago
Emergent BioSolutions Joins Effort to Combat National Public Health Threat From Opioid Overdose Through Acquisition of Adapt Pharma and Its Flagship Product NARCAN® (naloxone HCl) Nasal Spray
Acquisition advances Emergent’ s mission, vision and strategic growth plan by: Diversifying and expanding company’ s presence within the public health threats market to respond to the opioid crisis, declared ...
- Investor's Business Daily•last month
IBD Stock Of The Day: Vertex Pharma Nears Third Breakout Of 2018
Vertex Pharmaceuticals is the IBD Stock Of The Day as shares near a breakout amid a flurry of recent news surrounding its cystic fibrosis treatments.
Markit•last monthSee what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- GlobeNewswire•last month
Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
GAITHERSBURG, Md., Aug. 17, 2018-- Emergent BioSolutions Inc. announced today that a member of the company’ s senior management team will participate in the following investor conferences during the third ...
- American City Business Journals•last month
Two Maryland biotechs get $36 million to aid in new vaccine development
The project will be funded by Norway's Coalition for Epidemic Preparedness Innovations, which aims to develop vaccines to stop future epidemics.
- GlobeNewswire•last month
CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
OSLO, Norway, BALTIMORE and GAITHERSBURG, Md., Aug. 16, 2018-- CEPI today announced a new collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. under which they will receive up ...
- GlobeNewswire•last month
Report: Developing Opportunities within RA PHARMCTL INC, Oclaro, Emergent Biosolutions, Kennametal, Instructure, and Donegal Group — Future Expectations, Projections Moving into 2018
NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of RA ...
- Motley Fool•last month
5 Promising Vaccines in Development -- and the Stocks Poised to Profit From Them
Nearly $5 billion in combined annual sales could be on the way from these top vaccines in development.
- Thomson Reuters StreetEvents•last month
Edited Transcript of EBS earnings conference call or presentation 2-Aug-18 9:00pm GMT
Q2 2018 Emergent BioSolutions Inc Earnings Call
- The Wall Street Journal•last month
[$$] Emergent BioSolutions Buys PaxVax for $270 Million
Inc. has agreed to buy PaxVax Inc. for $270 million in cash. PaxVax, which makes vaccines for cholera, typhoid and other infectious diseases, is majority owned by private-equity firm Cerberus Capital Management, which invested $105 million in the company in late 2015. Ignition Growth Capital, a growth-equity firm, is a minority shareholder in the company.
Markit•last monthSee what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
Emergent Biosolutions Inc NYSE:EBS
